Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies

Rory Henderson1,2, Kara Anasti1, Kartik Manne1

  • 1Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Nature Communications
|November 3, 2024
PubMed
Summary

Developing an HIV-1 vaccine requires precise engineering of immunogens to induce broadly neutralizing antibodies (bnAbs). This study precisely engineers immunogens by simulating antibody-Env interactions, guiding specific antibody mutations for effective HIV-1 vaccine design.